Cardio Diagnostics Holdings Inc. CDIO soars as the company secures a dedicated Current Procedural Terminology (CPT) Proprietary Laboratory Analysis (PLA) from the American Medical Association (AMA) for its AI-powered coronary heart disease (CHD) detection test, PrecisionCHD.
The receipt of the CPT PLA code marks a pivotal moment for Cardio Diagnostics as it paves the way for billing, payment, and wider adoption of its genetic-epigenetic diagnostic blood test for CHD. Effective from April 1, 2024, the code propels the company’s commercialization efforts forward.
Commenting on the development, Meesha Dogan, Ph.D., CEO of Cardio Diagnostics, stated, “Cardio Diagnostics is unwavering in its commitment to ensuring widespread accessibility to our solutions. The dedicated CPT PLA code for PrecisionCHD represents a crucial milestone in our commercialization strategy. With PrecisionCHD, we are optimistic about expanding equitable access to CHD diagnostics, improving patient health outcomes, and reducing healthcare costs.”
Related News: Why Bitcoin Miners Hut 8 Corp And Hive Digital Technologies Stocks Are Climbing
CDIO Price Action: As per Benzinga Pro, Cardio Diagnostics shares surge by 39% to $3.46 at the time of publication.
Image: Pete Linforth from Pixabay